Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03504189
Other study ID # CLP1000
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2018
Est. completion date November 8, 2018

Study information

Verified date February 2020
Source Nuvo-Group, Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical study will evaluate the safety of PregSense™ and Comparative Performance of PregSense™ versus CTG in Prenatal Monitoring of Pregnant subjects.


Description:

PregSense™ is a maternal-fetal monitor that non-invasively measures and displays fetal heart rate, maternal hear rate and uterine contractions. This study will be performed to collect and digitally record data from PregSense™ and the standard of care (CTG) in order to provide evidence of safety and agreement between PregSense™ and the gold standard NST device.


Recruitment information / eligibility

Status Completed
Enrollment 151
Est. completion date November 8, 2018
Est. primary completion date June 27, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Female age between 18-50

- Gestational age > 32 + 0 weeks

- Singleton gestation

- Ability to understand and sign informed consent

Exclusion Criteria:

- BMI (Body Mass Index) = 45 and =15 prior pregnancy

- Multiple gestation

- Uncontrolled Hypertension

- Fetal Anomaly

- Subjects with skin problems in the abdominal area (such as flesh wounds, cuts in the skin, skin rashes, etc.)

- Subjects with implanted electronic devices (pacemaker, defibrillator, etc.)

- Subjects who, in the judgement of the investigator, are likely to be non-compliant or uncooperative during the study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PregSense™
PregSense™ wearable device will be applied for maternal-fetal monitoring
Cardiotocopraphy (CTG)
Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring

Locations

Country Name City State
Germany Heidelberg University Womens Hospital Heidelberg
Israel Hadassah-Hebrew University Medical Center Jerusalem
United States Eastern Virginia Medical School Norfolk Virginia
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Nuvo-Group, Ltd.

Countries where clinical trial is conducted

United States,  Germany,  Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety Measures Evaluate device related adverse events Through study completion, an average of 1 hour
Primary Fetal Heart Rate Provide evidence of safety and FHR agreement between PregSense™ and the standard of care devices (i.e. CTG) 30 Minutes
Primary Maternal Heart Rate Provide evidence of safety and agreement between MHR collected via the PregSense™ and the standard of care devices (i.e. CTG) 30 MInutes
Secondary Uterine Contractions Compare uterine contractions from Pregsense™ versus CTG. 30 Minutes
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Completed NCT02379728 - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth N/A